CompletedNot Applicable

A Serum Galectin-3 Levels in Placenta Accreta Spectrum Pregnancies

Turkey (Türkiye)60 participantsStarted 2021-12-01

Plain-language summary

Placenta Accreta Spectrum (PAS) represents a significant cause of maternal morbidity and mortality, causing complications that surpass those posed by most routine obstetric issues. As such, early detection and proper management of PAS can significantly improve pregnancy outcomes. This study provides an in-depth examination of the serum levels of Galectin-3, a β-galactoside-binding protein, in women experiencing Placenta Accreta Spectrum compared to those with normal pregnancies.

Who can participate

Age range20 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * PAS diagnosis Exclusion Criteria:Systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. Cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection. \-

What they're measuring

Galectin 3

Timeframe: 34-36 weeks of gestation

Trial details

NCT IDNCT05945446

SponsorNecmettin Erbakan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-01-01

View on ClinicalTrials.gov More Placenta Accreta, Third Trimester trials